Cargando…

Platinum-based neoadjuvant chemotherapy in BRCA1-positive breast cancer: a retrospective cohort analysis and literature review

BACKGROUND: There is increasing evidence of high platinum sensitivity in BRCA-associated breast cancer. However, evidence from randomized trials is lacking. The aim of this study was to analyze the results of platinum-based chemotherapy for BRCA1-positive breast cancer in a neoadjuvant setting. METH...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sæther, Nikolai Havn, Skuja, Elina, Irmejs, Arvids, Maksimenko, Jelena, Miklasevics, Edvins, Purkalne, Gunta, Gardovskis, Janis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5924493/ https://www.ncbi.nlm.nih.gov/pubmed/29719582 http://dx.doi.org/10.1186/s13053-018-0092-2

Ejemplares similares

Ultrasound guided needle biopsy of axilla to evaluate nodal metastasis after preoperative systemic therapy in cohort of 106 breast cancers enriched with BRCA1/2 pathogenic variant carriers
por: Līcīte, Baiba, et al.
Publicado: (2021)

Prognostic role of BRCA1 mutation in patients with triple-negative breast cancer
por: MAKSIMENKO, JELENA, et al.
Publicado: (2014)

BRCA1 mutation in the Triple- Negative Breast Cancer Group
por: Maksimenko, Jelena, et al.
Publicado: (2012)

Genotype-phenotype correlations among BRCA1 4153delA and 5382insC mutation carriers from Latvia
por: Plakhins, Grigorijs, et al.
Publicado: (2011)

Pregnancy after breast cancer in BRCA1/2 mutation carriers
por: Maksimenko, Jelena, et al.
Publicado: (2022)

Pathological complete response to neoadjuvant chemotherapy in triple negative breast cancer – single hospital experience
por: Sivina, Elina, et al.
Publicado: (2023)

Comment on the article Genetic contribution to all cancers: the first demonstration using the model of breast cancers from Poland stratified by age at diagnosis and tumour pathology by Lubinski et al., Breast Cancer Res Treat 2008 Apr 15
por: Irmejs, Arvids, et al.
Publicado: (2008)

Platinum-Based Chemotherapy Secures Effective Local Control for Very Advanced Hereditary Triple-Negative Breast Cancer with Life-Threatening Bleeding
por: Irmejs, Arvids, et al.
Publicado: (2017)

High frequency of pathogenic non-founder germline mutations in BRCA1 and BRCA2 in families with breast and ovarian cancer in a founder population
por: Maksimenko, J., et al.
Publicado: (2018)

BRCA1/2 mutation screening in high-risk breast/ovarian cancer families and sporadic cancer patient surveilling for hidden high-risk families
por: Berzina, Dace, et al.
Publicado: (2013)

High expression of miR-214 is associated with a worse disease-specific survival of the triple-negative breast cancer patients
por: Kalniete, Dagnija, et al.
Publicado: (2015)

Pilot Study on Low Penetrance Breast and Colorectal Cancer Predisposition Markers in Latvia
por: Irmejs, Arvids, et al.
Publicado: (2006)

Body mass index and nipple preservation are major contributors to satisfaction and aesthetic outcome rates after implant-based immediate breast reconstruction
por: Ukleikins, Stanislavs, et al.
Publicado: (2019)

Challenges in the management of a patient with Cowden syndrome: case report and literature review
por: Melbārde-Gorkuša, Inga, et al.
Publicado: (2012)

Clinical, Molecular and Geographical Features of Hereditary Breast/Ovarian Cancer in Latvia
por: Gardovskis, Andris, et al.
Publicado: (2005)

Effectiveness of Secondary Risk–Reducing Strategies in Patients With Unilateral Breast Cancer With Pathogenic Variants of BRCA1 and BRCA2 Subjected to Breast-Conserving Surgery: Evidence-Based Simulation Study
por: Maksimenko, Jelena, et al.
Publicado: (2022)

Correction: Effectiveness of Secondary Risk–Reducing Strategies in Patients With Unilateral Breast Cancer With Pathogenic Variants of BRCA1 and BRCA2 Subjected to Breast-Conserving Surgery: Evidence-Based Simulation Study
por: Maksimenko, Jelena, et al.
Publicado: (2023)

Chromothripsis and progression-free survival in metastatic colorectal cancer
por: Skuja, Elina, et al.
Publicado: (2017)

Allelic variants of breast cancer susceptibility genes PALB2 and RECQL in the Latvian population
por: Hilz, Philip, et al.
Publicado: (2019)

A novel frequent BRCA1 recurrent variant c.5117G > A (p.Gly1206Glu) identified after 20 years of BRCA1/2 research in the Baltic region: cohort study and literature review
por: Loza, P., et al.
Publicado: (2021)

Polygenic Risk Score Predicts Modified Risk in BRCA1 Pathogenic Variant c.4035del and c.5266dup Carriers in Breast Cancer Patients
por: Berga-Švītiņa, Egija, et al.
Publicado: (2023)

Hereditary Colorectal Cancer (CRC) Program in Latvia
por: Irmejs, Arvids, et al.
Publicado: (2003)

Can We Predict Differentiated Thyroid Cancer Behavior? Role of Genetic and Molecular Markers
por: Niciporuka, Rita, et al.
Publicado: (2021)

Population screening for hereditary and familial cancer syndromes in Valka district of Latvia
por: Vanags, Andrejs, et al.
Publicado: (2010)

Pathogenic APC Variants in Latvian Familial Adenomatous Polyposis Patients
por: Daneberga, Zanda, et al.
Publicado: (2019)

Bladder cancer trends in Latvia during 1990–2017: incidence, mortality, and survival rates
por: Bitiņa-Barlote, Ērika, et al.
Publicado: (2021)

Platinum-Based Neoadjuvant Chemotherapy for Breast Cancer With BRCA Mutations: A Meta-Analysis
por: Wang, Chang-Jun, et al.
Publicado: (2020)

An Effect of Culture Media on Epithelial Differentiation Markers in Breast Cancer Cell Lines MCF7, MDA-MB-436 and SkBr3
por: Pirsko, Valdis, et al.
Publicado: (2018)

The CHEK2 del5395 is a founder mutation without direct effects for cancer risk in the latvian population
por: Plonis, J, et al.
Publicado: (2016)

Evaluation and Predictive Factors of Complete Response in Rectal Cancer after Neoadjuvant Chemoradiation Therapy
por: Kokaine, Linda, et al.
Publicado: (2021)

The effect of neoadjuvant platinum-based chemotherapy in BRCA mutated triple negative breast cancers -systematic review and meta-analysis
por: Caramelo, Olga, et al.
Publicado: (2019)

Cumulative Small Effect Genetic Markers and the Risk of Colorectal Cancer in Poland, Estonia, Lithuania, and Latvia
por: Serrano-Fernandez, Pablo, et al.
Publicado: (2015)

Significance of platinum distribution to predict platinum resistance in ovarian cancer after platinum treatment in neoadjuvant chemotherapy
por: Uno, Kaname, et al.
Publicado: (2022)

Determination of BRCAness Phenotype in Breast Tumors for the Appointment of Neoadjuvant Chemotherapy Based on Platinum and Taxanes
por: Tsyganov, Matvey Mihajlovich, et al.
Publicado: (2022)

The Fetal Phenotype of Noonan Syndrome Caused by Severe, Cancer-Related PTPN11 Variants
por: Malniece, Ieva, et al.
Publicado: (2020)

Complete Pathological Response to Platinum-Based Neoadjuvant Chemotherapy in BRCA2-Associated Locally Advanced Pancreatic Cancer: A Case Report and Literature Review
por: Asiri, Mohamed S, et al.
Publicado: (2023)

Neoadjuvant chemotherapy with Cisplatin in BRCA1 mutation carriers – results of treatment
por: Byrski, T, et al.
Publicado: (2012)

BRCA-mutated gastric adenocarcinomas are associated with chromosomal instability and responsiveness to platinum-based chemotherapy
por: Oh, Ji Hyun, et al.
Publicado: (2023)

Germline BRCA, chemotherapy response scores, and survival in the neoadjuvant treatment of ovarian cancer
por: Lee, Yong Jae, et al.
Publicado: (2020)

Predictive value of BRCA1/2 mRNA expression for response to neoadjuvant chemotherapy in BRCA‐negative breast cancers
por: Xu, Ye, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_sfkt0b0lf66g8brodnscblnd2r